Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Naltrexone And Bupropion

Stage Phase 3Stale

Sponsor Orexigen Therapeutics, Inc

Class Opioid and antidepressant

Mechanism opioid antagonist and aminoketone antidepressant

Sources

registry, as of 2014-11-21Stale

https://clinicaltrials.gov/study/NCT00532779

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects. Overall status COMPLETED. Phases PHASE3. Lead sponsor Orexigen Therapeutics, Inc. Enrollment 1742. Conditions Obesity; Overweight. The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity. Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease NB16 39.49 Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease NB32 47.98 Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease Placebo 16.44 Body Weight- Proportion of Subjects With ≥10% Decrease NB16 20.17 Body Weight- Proportion of Subjects With ≥10% Decrease NB32 24.63 Body Weight- Proportion of Subjects With ≥10% Decrease Placebo 7.44 diarrhoea NB16 31 nausea NB16 155 vomiting NB16

ClinicalTrials.gov NCT00532779 protocol and results modules

registry, as of 2014-11-21Stale

https://clinicaltrials.gov/study/NCT00567255

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects. Overall status COMPLETED. Phases PHASE3. Lead sponsor Orexigen Therapeutics, Inc. Enrollment 1496. Conditions Obesity; Overweight. The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity. Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28 NB32 55.64 Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28 Placebo 17.54 Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56 NB32 50.48 Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56 Placebo 17.11 Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28 NB32 27.27 Body Weight- Proportion of Subjects With ≥10%

ClinicalTrials.gov NCT00567255 protocol and results modules

registry, as of 2014-12-17Stale

https://clinicaltrials.gov/study/NCT00456521

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program. Overall status COMPLETED. Phases PHASE3. Lead sponsor Orexigen Therapeutics, Inc. Enrollment 793. Conditions Obesity; Overweight. The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program than with group lifestyle modification alone. Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease NB32 66.39 Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease Placebo 42.49 Body Weight- Proportion of Subjects With ≥10% Decrease NB32 41.49 Body Weight- Proportion of Subjects With ≥10% Decrease Placebo 20.21 diarrhoea NB32 43 nausea NB32 199 vomiti

ClinicalTrials.gov NCT00456521 protocol and results modules

registry, as of 2014-11-21Stale

https://clinicaltrials.gov/study/NCT00474630

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Orexigen Therapeutics, Inc. Enrollment 505. Conditions Obesity; Overweight; Diabetes Mellitus, Type 2. The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes. Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease NB32 44.53 Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease Placebo 18.87 Body Weight- Proportion of Subjects With ≥10% Decrease NB32 18.49 Body Weight- Proportion of Subjects With ≥10% Decrease Placebo 5.66 diarrhoea NB32 52 nausea NB32 141 vomiting NB32 61 diarrhoea Placebo 16 nausea Placebo 12 vomiting Placebo 6

ClinicalTrials.gov NCT00474630 protocol and results modules

registry, as of 2023-03-08Stale

https://clinicaltrials.gov/study/NCT03045341

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment. Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Yale University. Enrollment 136. Conditions Binge-eating Disorder; Obesity. This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in co deaths Placebo 0 diarrhea Placebo 9 nausea Placebo 5 vomiting Placebo 0 deaths NB Medication 0 diarrhea NB Medication 3 nausea NB Medication 13 vomiting NB Medication 1 deaths BWL + Placebo 0 diarrhea BWL + Placebo 3 nausea BWL + Placebo 3 vomiting BWL + Placebo 1

ClinicalTrials.gov NCT03045341 protocol and results modules

registry, as of 2026-08-26Stale

https://clinicaltrials.gov/study/NCT04599478

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1). Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Yale University. Enrollment 92. Conditions Loss-of-control Eating; Obesity/Overweight. This study will compare the effectiveness of behavioral and pharmacologic treatments, alone and in combination, for the treatment of loss-of-control eating and weight following bariatric surgery. This is an acute treatment comparing behavioral weight loss alone or in combination deaths Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) Medication 0 diarrhea Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) Medication 3 nausea Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) Medication 7 vomiting Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) Medication 2 deaths BWL + Placebo 0 diarrhea BWL + Placebo 3 nausea BWL +

ClinicalTrials.gov NCT04599478 protocol and results modules

registry, as of 2026-09-21Stale

https://clinicaltrials.gov/study/NCT05157698

Pharmacological and Behavioral Treatment After Bariatric Surgery. Overall status COMPLETED. Phases PHASE3. Lead sponsor Yale University. Enrollment 84. Conditions Obesity. This study will compare the effectiveness of behavioral and pharmacologic treatment, alone and combined, for improvements in weight loss, cardiovascular risk factors, and psychosocial functioning following metabolic and bariatric surgery.

ClinicalTrials.gov NCT05157698 protocol and results modules

registry, as of 2024-02-02Stale

https://clinicaltrials.gov/study/NCT03047005

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy. Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Yale University. Enrollment 68. Conditions Binge-Eating Disorder; Obesity. This study will test the effectiveness and relative efficacy of naltrexone/bupropion medication as a maintenance therapy for the treatment of binge eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst responders to acute treatments, naltre deaths NB Medication 0 diarrhea NB Medication 2 nausea NB Medication 8 vomiting NB Medication 3 deaths Placebo 0 diarrhea Placebo 5 nausea Placebo 3 vomiting Placebo 3

ClinicalTrials.gov NCT03047005 protocol and results modules

registry, as of 2026-08-26Stale

https://clinicaltrials.gov/study/NCT04605081

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a). Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Yale University. Enrollment 24. Conditions Loss-of-Control Eating; Obesity/Overweight. This study will test the effectiveness of naltrexone/bupropion medication as a maintenance therapy for the treatment of loss-of-control eating and weight loss following bariatric surgery. This is a controlled test of whether, amongst responders to acute treatments, naltrexone/bup deaths Naltrexone+Bupropion Medication 0 nausea Naltrexone+Bupropion Medication 0 deaths Placebo 0 nausea Placebo 1

ClinicalTrials.gov NCT04605081 protocol and results modules

registry, as of 2026-01-09Stale

https://clinicaltrials.gov/study/NCT03946111

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders. Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Yale University. Enrollment 3. Conditions Binge-Eating Disorder; Obesity. This study will test the relative efficacy and effectiveness of the combination of naltrexone and bupropion (NB) medication as a treatment for binge-eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst non-responders to acute treatments, N deaths Naltrexone/Bupropion 0 diarrhea Naltrexone/Bupropion 0 nausea Naltrexone/Bupropion 0 vomiting Naltrexone/Bupropion 0 deaths Placebo 0 diarrhea Placebo 0 nausea Placebo 0 vomiting Placebo 0

ClinicalTrials.gov NCT03946111 protocol and results modules

registry, as of 2008-04-22Stale

https://clinicaltrials.gov/study/NCT00364871

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Orexigen Therapeutics, Inc. Enrollment 410. Conditions Obesity. The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.

ClinicalTrials.gov NCT00364871 protocol and results modules

registry, as of 2026-07-08Stale

https://clinicaltrials.gov/study/NCT07398404

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients. Overall status NOT_YET_RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Medical University of South Carolina. Enrollment 64. Conditions Obesity; Smoking Cessation; Bariatric Surgery Patients. The purpose of this research study is to evaluate a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery. The intervention will be compared to a standa

ClinicalTrials.gov NCT07398404 protocol and results modules

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b

CONTRAVE is a combination of naltrexone, an opioid antagonist, and bupropion, an aminoketone antidepressant

DailyMed label description

Studies

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Registry NCT00532779

Phase Phase 3

Status Completed

Enrollment 1742

NB16

Weeks 56

Comparator placebo

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 39.49 %, week 56Stale

participants with at least 10 percent body weight loss, 20.17 %, week 56Stale

participants with diarrhoea, 31 participantsStale

participants with nausea, 155 participantsStale

participants with vomiting, 36 participantsStale

NB32

Weeks 56

Comparator placebo

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 47.98 %, week 56Stale

participants with at least 10 percent body weight loss, 24.63 %, week 56Stale

participants with diarrhoea, 26 participantsStale

participants with nausea, 171 participantsStale

participants with vomiting, 56 participantsStale

Placebo

Weeks 56

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 16.44 %, week 56Stale

participants with at least 10 percent body weight loss, 7.44 %, week 56Stale

participants with diarrhoea, 28 participantsStale

participants with nausea, 30 participantsStale

participants with vomiting, 14 participantsStale

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

Registry NCT00567255

Phase Phase 3

Status Completed

Enrollment 1496

NB32

Weeks 28

Comparator placebo

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 55.64 %, week 28Stale

participants with at least 5 percent body weight loss, 50.48 %, week 56Stale

participants with at least 10 percent body weight loss, 27.27 %, week 28Stale

participants with diarrhoea, 55 participantsStale

participants with nausea, 290 participantsStale

participants with vomiting, 84 participantsStale

Placebo

Weeks 28

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 17.54 %, week 28Stale

participants with at least 5 percent body weight loss, 17.11 %, week 56Stale

participants with at least 10 percent body weight loss, 7.02 %, week 28Stale

participants with diarrhoea, 18 participantsStale

participants with nausea, 34 participantsStale

participants with vomiting, 10 participantsStale

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

Registry NCT00456521

Phase Phase 3

Status Completed

Enrollment 793

NB32

Weeks 56

Comparator placebo

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 66.39 %, week 56Stale

participants with at least 10 percent body weight loss, 41.49 %, week 56Stale

participants with diarrhoea, 43 participantsStale

participants with nausea, 199 participantsStale

participants with vomiting, 64 participantsStale

Placebo

Weeks 56

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 42.49 %, week 56Stale

participants with at least 10 percent body weight loss, 20.21 %, week 56Stale

participants with diarrhoea, 15 participantsStale

participants with nausea, 21 participantsStale

participants with vomiting, 13 participantsStale

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

Registry NCT00474630

Phase Phase 3

Status Completed

Enrollment 505

NB32

Weeks 56

Comparator placebo

Population Obesity; Overweight; Diabetes Mellitus, Type 2

participants with at least 5 percent body weight loss, 44.53 %, week 56Stale

participants with at least 10 percent body weight loss, 18.49 %, week 56Stale

participants with diarrhoea, 52 participantsStale

participants with nausea, 141 participantsStale

participants with vomiting, 61 participantsStale

Placebo

Weeks 56

Population Obesity; Overweight; Diabetes Mellitus, Type 2

participants with at least 5 percent body weight loss, 18.87 %, week 56Stale

participants with at least 10 percent body weight loss, 5.66 %, week 56Stale

participants with diarrhoea, 16 participantsStale

participants with nausea, 12 participantsStale

participants with vomiting, 6 participantsStale

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Registry NCT03045341

Phase Phase 2/3

Status Completed

Enrollment 136

Start 2017-02-27

Primary completion 2021-07-23

Study completion 2022-12-16

BWL + NB medication

Regimen daily

Weeks 16

Comparator placebo

Population Binge-eating Disorder; Obesity

deaths

participants with diarrhea, 3 participantsStale

participants with nausea, 13 participantsStale

participants with vomiting, 1 participantsStale

BWL + Placebo

Regimen daily

Weeks 16

Population Binge-eating Disorder; Obesity

deaths

participants with diarrhea, 9 participantsStale

participants with nausea, 5 participantsStale

participants with vomiting, 0 participantsStale

NB medication

Regimen daily

Weeks 16

Comparator placebo

Population Binge-eating Disorder; Obesity

Placebo

Regimen daily

Weeks 16

Population Binge-eating Disorder; Obesity

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

Registry NCT04599478

Phase Phase 2/3

Status Completed

Enrollment 92

Start 2021-06-29

Primary completion 2026-06-04

Study completion 2026-06-04

Catalyst Primary completion. 2026-06-04. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication

Regimen daily

Weeks 16

Comparator placebo

Population Loss-of-control Eating; Obesity/Overweight

deaths

participants with diarrhea, 3 participantsStale

participants with nausea, 7 participantsStale

participants with vomiting, 2 participantsStale

BWL + Placebo

Regimen daily

Weeks 16

Population Loss-of-control Eating; Obesity/Overweight

deaths

participants with diarrhea, 3 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

NB medication

Regimen daily

Weeks 16

Comparator placebo

Population Loss-of-control Eating; Obesity/Overweight

Placebo

Regimen daily

Weeks 16

Population Loss-of-control Eating; Obesity/Overweight

Pharmacological and Behavioral Treatment After Bariatric Surgery

Registry NCT05157698

Phase Phase 3

Status Completed

Enrollment 84

Start 2022-01-13

Primary completion 2026-05-25

Study completion 2026-05-25

Catalyst Primary completion. 2026-05-25. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

BWL + NB medication

Regimen daily

Comparator placebo

Population Obesity

BWL + Placebo

Regimen daily

Population Obesity

NB medication

Regimen daily

Comparator placebo

Population Obesity

Placebo

Regimen daily

Population Obesity

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

Registry NCT03047005

Phase Phase 2/3

Status Completed

Enrollment 68

Start 2017-08-28

Primary completion 2021-12-16

Study completion 2022-12-16

NB medication

Regimen daily

Weeks 16

Comparator placebo

Population Binge-Eating Disorder; Obesity

deaths

participants with diarrhea, 2 participantsStale

participants with nausea, 8 participantsStale

participants with vomiting, 3 participantsStale

Placebo

Regimen daily

Weeks 16

Population Binge-Eating Disorder; Obesity

deaths

participants with diarrhea, 5 participantsStale

participants with nausea, 3 participantsStale

participants with vomiting, 3 participantsStale

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Registry NCT04605081

Phase Phase 2/3

Status Completed

Enrollment 24

Start 2022-06-10

Primary completion 2026-06-04

Study completion 2026-06-04

Catalyst Primary completion. 2026-06-04. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Naltrexone+Bupropion Medication

Regimen daily

Comparator placebo

Population Loss-of-Control Eating; Obesity/Overweight

deaths

participants with nausea, 0 participantsStale

Placebo

Regimen daily

Population Loss-of-Control Eating; Obesity/Overweight

deaths

participants with nausea, 1 participantsStale

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

Registry NCT03946111

Phase Phase 2/3

Status Completed

Enrollment 3

Start 2019-08-07

Primary completion 2024-12-05

Study completion 2024-12-05

Naltrexone/Bupropion

Comparator placebo

Population Binge-Eating Disorder; Obesity

deaths

participants with diarrhea, 0 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

Placebo

Population Binge-Eating Disorder; Obesity

deaths

participants with diarrhea, 0 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

Registry NCT00364871

Phase Phase 2

Status Completed

Enrollment 410

1

Comparator placebo

Population Obesity

2

Comparator placebo

Population Obesity

3

Comparator placebo

Population Obesity

4

Comparator placebo

Population Obesity

5

Population Obesity

6

Population Obesity

7

Comparator placebo

Population Obesity

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

Registry NCT07398404

Phase Phase 1/2

Status Not yet recruiting

Enrollment 64

Start 2026-09-01

Primary completion 2030-12-31

Study completion 2031-06-30

Catalyst Primary completion. 2030-12-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

MHBC Intervention Group

Regimen twice daily

Population Obesity; Smoking Cessation; Bariatric Surgery Patients

Control Group

Regimen twice daily

Population Obesity; Smoking Cessation; Bariatric Surgery Patients